Location:
Hyatt Regency Denver at the Colorado Convention Center
650 15th St
Denver, CO 80202
Hotel Phone: (303) 436-1234
Meeting Room:
Capitol Ballroom 4-7 (Fourth Floor)
Schedule (MST):
5:30 AM – 6:00 AM — Registration and Breakfast Buffet
6:00 AM – 7:30 AM — Educational Program
There is no registration fee for these events. However, preregistration is required as seating is limited.
Faculty:
Jenny Dahl, PA-C
Physician Assistant
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Aaron T Gerds, MD, MS
Assistant Professor of Medicine, Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio
Emily A Knight, APRN, MSN, NP, OCN
Hematology Nurse Practitioner
Mayo Clinic Cancer Center
Phoenix, Arizona
Daniel A Pollyea, MD, MS
Associate Professor of Medicine
Division of Hematology
University of Colorado School of Medicine
Clinical Director of Leukemia Services
Aurora, Colorado
Sarah K Swanson, APN-BC
Nurse Practitioner
Rush University Medical Center
Chicago, Illinois
Moderator:
Neil Love, MD
Research To Practice
Miami, Florida
Meeting space has been assigned to provide a satellite symposium supported by Incyte Corporation (via an educational grant) during the Oncology Nursing Society’s (ONS) 42nd Annual Congress, May 3-7, 2017 in Denver, Colorado. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
MODULE 1: Overview of Myeloproliferative Neoplasms (MPNs)
DISCUSSION TOPICS
- Disease characteristics and spectrum of clinical issues associated with myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET)
- Shared biology and clinical features of MPNs
- Incidence of progression for ET and PV to MF
- Risk of leukemic transformation in patients with MPNs
- Clinical significance of the JAK-STAT pathway and associated driver mutations in MPN development
MODULE 2: Myelofibrosis
DISCUSSION TOPICS
- Diagnosis, symptoms and clinical course of MF; primary versus secondary MF
- Risk stratification for patients with MF: International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS) and DIPSS Plus
- Potentially curative role of allogeneic stem cell transplant; identification of appropriate patients and associated risk of mortality
- Role of splenectomy in patients with MF
- Effectiveness of erythropoiesis-stimulating agents and growth factors in reversing MF-associated anemia and neutropenia
- Mechanism of action of the JAK1/2 inhibitor ruxolitinib; rapidity and durability of response and role in symptom management
- Side effects and toxicities associated with ruxolitinib (eg, thrombocytopenia, anemia, neutropenia)
- Monitoring of blood counts in patients receiving ruxolitinib and dosing strategies in patients with dropping platelet or red blood cell counts
- Incidence of infections and importance of assessing risk factors for tuberculosis prior to initiating therapy with ruxolitinib
- Continuation of JAK1/2 inhibitor therapy in patients with minimal response in the spleen but stable disease and resolution of symptoms; dose escalation in patients with no or suboptimal response
- Importance of gradual tapering versus abrupt discontinuation when stopping ruxolitinib
- Commonly used approaches in the management of progressive MF; promising investigational agents and regimens
MODULE 3: Polycythemia Vera
DISCUSSION TOPICS
- Typical presentation, symptoms and clinical course of PV
- Incidence of venous and arterial thrombosis among patients with PV
- Primary treatment approaches in PV, including phlebotomy, antiplatelet/anticoagulation therapy and cytoreductive therapy (ie, hydroxyurea or interferon alpha)
- Management of common hydroxyurea-associated side effects
- Time course to and development of hydroxyurea resistance
- Biologic rationale for JAK1/2 inhibitor activity in PV
- Integration of ruxolitinib into the treatment algorithm for patients who are hydroxyurea-refractory or intolerant
- Rationale for differences in approach to ruxolitinib dosing for patients with PV versus MF
MODULE 4: Essential Thrombocythemia
DISCUSSION TOPICS
- Criteria for diagnosis of ET, symptoms and clinical course
- Risk of thrombosis and bleeding in patients with ET and correlation with other cardiovascular risk factors (eg, weight, high blood pressure, diabetes, smoking)
- Significance of the CALR mutation: Decreased risk of thrombosis in patients with ET
- Systemic therapy for low-risk, asymptomatic versus high-risk ET
- Treatment options for patients with high-risk ET who are resistant or intolerant to hydroxyurea: anagrelide and interferon alpha
- Available data with and current role, if any, of ruxolitinib in the management of ET
Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of myeloproliferative neoplasms.
Learning Objectives and Goals:
Upon completion of this activity, participants should be able to:
- Use an understanding of disease biology and natural history to communicate diagnosis and prognosis to patients with polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF).
- Discuss the benefits and risks associated with local and systemic therapies used in the evidence-based treatment of PV, ET and MF.
- Recognize the FDA approval of ruxolitinib for patients with PV, and provide related counseling to individuals who may be appropriate for therapeutic intervention with this agent.
- Counsel patients with JAK2 mutation-positive and mutation-negative MF about the efficacy and safety of ruxolitinib treatment.
- Appraise the role of ruxolitinib in patients with MF and thrombocytopenia, anemia or compromised renal function.
- Develop a plan to manage the side effects associated with ruxolitinib to support quality of life and continuation of treatment.
- Recall ongoing trials of investigational approaches in MF, PV and ET, and obtain consent and refer patients for study participation.
Accreditation Statements:
Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 1.5 contact hours is provided by Research To Practice.
This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.
To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity. Your certificate will be mailed to you within 4 to 6 weeks. International attendees, please note: In order for a certificate of completion to be issued, you must provide a valid email address.
ONCC/ILNA Certification Information:
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. Learners must apply for CNE credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2017/ILNA
Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center. Any off-label use as declared by the FDA will be identified.
Content Validation and Disclosures:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
Research To Practice staff and external reviewers — The scientific staff, planners, managers and reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporter:
This activity is supported by an educational grant from Incyte Corporation.
Hyatt Regency Denver at the Colorado Convention Center
650 15th Street
Denver, CO 80202
Hotel Phone: (303) 436-1234
Meeting Room:
Capitol Ballroom 4-7 (Fourth Floor)
The Hyatt Regency Denver at the Colorado Convention Center is the host hotel for the 2017 ONS Annual Congress.
Thank you for your interest in our CNE symposia series. At this time, online preregistration is closed for PART 5 – Myeloproliferative Neoplasms session. Onsite registration will be open starting at 5:30 AM (MST) on Friday, May 5th.
If you are interested in standing by for seating (day of the program), please visit our registration desk located outside the Capitol Ballroom 4-7, on the fourth floor of the Hyatt Regency Denver at the Colorado Convention Center hotel (650 15th St, Denver, CO 80202). You may arrive up to 30-minutes before the program start time and receive a stand by ticket.
If seats become available for the program, we will accept stand by registrations on a first come, first served basis. Please note onsite registration does not guarantee participation in the session or meal service. If you have any questions, please feel free to contact us via email atMeetings@ResearchToPractice.com or call (800) 233-6153.
|
